If I’d put £1,000 in GSK shares 6 months ago, here’s what I’d have now

What’s going on with GSK shares? The pharmaceutical giant has seen its share price surge in recent months. Dr James Fox takes a closer look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Couple working from home while daughter watches video on smartphone with headphones on

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE:GSK) shares are up 18.9% over six months. And much of that growth has come in the past month.

So if I had invested £1,000 in GSK stock six months, today I’d have £1,189, plus about £10 in the form of dividends — paid on 11 January.

That’s clearly a pretty successful investment. However, is this the start of a sustained rally, or just market volatility? Let’s explore.

Litigation

GSK stock has struggled in recent years due to litigation surrounding the discontinued heartburn Zantac drug. In 2019, concerns surfaced about potential cancer risks associated with an impurity found in Zantac and similar ranitidine drugs.

GSK’s stock has been volatile since then, experiencing both dips and rises as legal developments unfold. Recent settlements have helped boost the stock price somewhat.

However, the litigation surrounding Zantac is ongoing, with potential liabilities for GSK still to be determined. This uncertainty hangs over the company and its stock performance, and this remains a risk.

Improving performance

Of course, litigation isn’t the only thing impacting the GSK performance. In fact, since its split from its consumer health division — now Haleon — the company has performed rather well.

The latest quarterly results from GSK reveal an impressive double-digit growth in sales and profits. In turn, this underscores the company’s robust financial strength as well as its commitment to growth.

Excluding pandemic-related solutions, sales surged by 16% to reach £8.1bn. Meanwhile, adjusted operating profit saw a remarkable 22% increase to £2.8bn.

More specifically, investors were excited by the highly successful launch of the RSV (respiratory syncytial virus) vaccine, Arexvy. The vaccine performed extraordinarily well within its first year, with projected sales expected to surpass £1bn.

To date, Arexvy has delivered £700m in revenue, and this contributed to a booming vaccines segment, which was up 33% at Q3.

Of course, there are concerns, including the non-renewal of Blenrep — a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma — in Europe.

In turn, this could present a challenge for the oncology business.

Cheap, but why?

From a quantitate perspective, GSK looks rather attractive. It trades at 10.3 times forward earnings, putting it at a discount of 64.9% to the sector.

And this top-grade valuation is present when we look at other metrics, including the EV-to-EBITDA ratio at 7.6. In turn, representing a 43.6% discount to the sector.

However, there are two things these metrics don’t take into account. The first is the ongoing litigation procedures and the impact this could have on future profitability.

And the next is growth. When we look at the price/earnings-to-growth (PEG) ratio, which sits at 2.11, we can see that this may be an issue. This metric, which is earnings adjusted for growth over three-to-five years, only suggests companies are undervalued if the ratio is below one.

However, I believe the earnings growth consensus for this stock is a little conservative. So maybe that PEG ratio should be a little lower — probably not below one.

Personally, I’m not buying GSK shares today, but I may be tempted in the future when the Zantac situation becomes clearer.

Despite the risks associated with the court cases, it could be a good stock to buy and forget about for 10 years. After all, pharma is a buoyant sector.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has no positions in any of the companies mentioned. The Motley Fool UK has recommended GSK and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s the best-performing FTSE 100 stock of the last 10 years

Private equity firm 3i has outperformed the rest of the FTSE 100 over the last 10 years. And its big…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Here’s why Warren Buffett is selling shares (and why I’m not)

Warren Buffett cited tax considerations as his reason for selling shares in Apple. But this isn’t something most UK investors…

Read more »

Investing Articles

What on earth is going on with the AstraZeneca share price?

The AstraZeneca share price has fallen 30% from its peak in August. Dr James Fox explains what’s going on with…

Read more »

Investing Articles

2 high-yield FTSE 100 shares I’d consider buying for passive income…and one I’d avoid

Some FTSE 100 stocks have eye-popping dividend yields. But will the passive income actually be dished out? Paul Summers takes…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

These 2 former stock market darlings are trying my patience! Time to sell?

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks.…

Read more »

Investing Articles

Here’s how I’d use £3,000 to target a second income that grows each year

Our writer explains the approach he'd take to trying to build a second income that gets bigger over time, by…

Read more »

Elevated view over city of London skyline
Investing Articles

Is it time to buy this incredible FTSE dividend share?

Christopher Ruane examines one FTSE 100 share with a phenomenal dividend history. Does a steep share price fall this year…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

This FTSE 100 share has just crashed another 20%. Its P/E is now just 9.9 so should I buy?

Harvey Jones was tempted to buy this FTSE 100 share after it crashed in October. Now it's crashed again, it…

Read more »